Scientific deep-dive
Zepbound for Sleep Apnea: What SURMOUNT-OSA Actually Found
On December 20, 2024 the FDA cleared Zepbound for obstructive sleep apnea, and no other drug of any kind holds that indication. The trials cut breathing interruptions by 25 to 29 an hour, and left the average participant still inside the moderate band.
On December 20, 2024 the FDA cleared Zepbound for obstructive sleep apnea. No other drug of any kind carries that indication.[6] The license is narrow. It covers adults who have obesity as well as OSA at the moderate-to-severe end, and it positions the drug beside a calorie deficit and more activity rather than in place of them. It works: in the two SURMOUNT-OSA trials, breathing interruptions fell by 25.3 and 29.3 an hour against 5.3 and 5.5 on placebo.[1] What almost no coverage mentions is where that leaves people. Subtract those changes from the trial's own starting points and the average participant still had moderate sleep apnea at week 52. This is a large improvement, and it is not a cure.
What the trials did
SURMOUNT-OSA was run as two separate 52-week trials rather than one. Trial 1 enrolled people who were not using positive airway pressure. Trial 2 enrolled people who were. Each assigned participants to placebo or to tirzepatide, at whichever of the two upper strengths (10 mg or 15 mg) the person tolerated. Both measured one primary endpoint: the change in the apnea-hypopnea index, meaning the number of times an hour that breathing stops or goes shallow during sleep.[1]
Splitting the trial that way was the right call, because the two groups are asking different questions. One is asking what the drug does for untreated apnea. The other is asking what it adds for someone already on a machine. Our sleep apnea condition page covers the condition itself, including who is at risk and how it is diagnosed.
The published numbers
| Trial 1 — not using PAP | Trial 2 — using PAP | |
|---|---|---|
| Mean AHI at baseline | 51.5 | 49.5 |
| Change on tirzepatide | −25.3 | −29.3 |
| Change on placebo | −5.3 | −5.5 |
| Treatment difference | −20.0 | −23.8 |
Tirzepatide also improved every prespecified secondary endpoint against placebo: body weight, hypoxic burden, high-sensitivity C-reactive protein, systolic blood pressure, and patient-reported sleep impairment and disturbance.[1] Whether gains such as the blood pressure and C-reactive protein changes came from the weight loss or from better breathing is the subject of a post hoc analysis of these trials. Gastrointestinal effects were the most commonly reported adverse events, mostly mild to moderate. That is the same profile the drug carries at any dose, covered in our constipation guide and the side-effect timeline.
Where that actually leaves you
Promotional coverage skips this step. The trial reports change in AHI, not the number people finished on. Do the subtraction yourself. In trial 1, a mean baseline of 51.5 less a mean change of 25.3 leaves about 26 events an hour. In trial 2, 49.5 less 29.3 leaves about 20.
Sleep apnea is graded as mild at 5 to 14.9 events an hour, moderate at 15 to 29.9, and severe at 30 or more.[3] So the average participant in both trials moved from severe apnea to moderate apnea. That is a meaningful shift and worth having. It is not the same as no longer having the condition, and someone reading “first drug approved for sleep apnea” could easily believe otherwise.
In trial 1, a mean baseline of 51.5 less a mean change of 25.3 leaves about 26 events an hour, which is still moderate sleep apnea.
Trial 2 has one more wrinkle. For its participants, PAP was withdrawn before the polysomnography and the questionnaires were administered.[2] The trial-2 figures therefore describe what tirzepatide did on its own for people who had been on a machine, not what the drug and the machine achieve together. Nothing in SURMOUNT-OSA measured the combination.
Sleep, as opposed to the index
An apnea-hypopnea index is a count. It is not the same as feeling rested, and a treatment can move one without moving the other. A 2025 analysis of the patient-reported measures collected inside SURMOUNT-OSA looked at this, and found significant improvements against placebo at week 52 in sleep-related impairment, sleep disturbance, daytime functioning and health-related quality of life, across several validated instruments.[2]
That matters. The count could have improved while people felt no different, and that is the outcome most drug trials in this space are not designed to detect.
What about the other GLP-1 drugs
Only tirzepatide has the indication. Liraglutide was tested for this a decade ago: SCALE Sleep Apnea randomized 359 adults with obesity and moderate or severe OSA who were unwilling or unable to use PAP, and over 32 weeks the AHI fell by 12.2 events an hour against 6.1 on placebo, with weight down 5.7% against 1.6%.[3] That is a real effect, and a fraction of what tirzepatide produced.
Semaglutide has no dedicated sleep apnea trial. If a seller markets a compounded semaglutide product for sleep apnea, that claim is not standing on a trial in this condition, and marketing an unapproved use is a pattern we track on the FDA warning letters page.
The coverage question
The approval changed who can plausibly get this covered. Before December 2024, a Zepbound prescription was a weight-management prescription, and a great many plans exclude weight-management drugs outright. An OSA diagnosis is a different clinical route, and some plans that refuse the first will consider the second. Anthem’s Medi-Cal plan is one example: it dropped Zepbound for weight loss in January 2026 but still considers prior authorization requests for sleep apnea. Medicaid draws the same line: its federal weight-loss exclusion is written against a use, not a drug. Because the indication belongs to the brand, our Zepbound for sleep apnea board lists only sellers that price brand Zepbound, with compounded tirzepatide left off.
It is not automatic. Expect prior authorization, expect a documented sleep study, and expect the plan to have its own criteria for what counts. Our insurance section tracks what individual plans publish, and the prior authorization letter generator assembles what a submission generally needs. What we cannot tell you is what your specific plan will do, and any seller who says they know is guessing.
If you are going through a telehealth seller, check that it can write the brand product at all, and how. The Virtual NP, a nurse-practitioner practice, prescribes brand Zepbound and offers prior-authorization help, with the drug paid to the pharmacy or through insurance. Brightmeds writes Zepbound vial prescriptions for a consult fee, and LillyDirect bills the drug separately.
Others sell brand Zepbound for cash beside their compounded plans: HeliMeds one order at a time with no auto-billing, RxION Health, WellMedRx and Tryozi by the month, and Layla on a monthly plan. Vytora Health lists both brand Zepbound and Mounjaro, and myRocky lists Mounjaro but not Zepbound. The molecule is the same, but only the Zepbound label carries the sleep apnea indication, which is the one an OSA-based coverage request leans on.
For what the drug does on the scale rather than in the sleep lab, our tirzepatide results timeline works through the SURMOUNT weight-loss trials, and the price tracker carries a dated figure for every seller we follow.
Frequently Asked Questions
References
- 1.Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity New England Journal of Medicine. 2024. PMID: 38912654.
- 2.Kanu C, Shinde S, Chakladar S, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity Sleep Medicine. 2025. PMID: 40774158.
- 3.Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial International Journal of Obesity. 2016. PMID: 27005405.
- 4.Bardóczi A, Matics ZZ, Turan C, et al. Efficacy of incretin-based therapies in obesity-related obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials Sleep Medicine Reviews. 2025. PMID: 40633481.
- 5.Li M, Lin H, Yang Q, et al. Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis Sleep. 2025. PMID: 39626095.
- 6.U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea — press announcement, December 20, 2024 FDA. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
Compare the sellers
Related research
What Sets the Price of Semaglutide: The Routes and the Four Variables
What decides what you pay for semaglutide without coverage: which brand, which strength, what a program counts as a month, and whether your plan refused the drug or one indication.
11 min read
Does Medicaid Cover Zepbound? The Federal Rule and the Sleep Apnea Indication
Medicaid is run state by state and, under federal law, each program may exclude weight-loss agents, but that exclusion attaches to a use rather than to a drug, which is why Zepbound's obstructive sleep apnea indication changes the conversation.
12 min read
Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers
Ozempic and Wegovy are the same molecule under different FDA approvals, and Medicaid's drug benefit follows the approved use, which is why the diabetes label clears and the weight-management label is the one a state may refuse under federal law.
12 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
GLP-1 Drugs and Type 1 Diabetes: The Label Says Unevaluated. Three Trials Disagree.
36% of people with type 1 diabetes and obesity hit a composite of time-in-range, low-glucose safety and 5% weight loss, against 0% on placebo. Total daily insulin fell about a third in a second trial.
7 min read
AOD-9604: What the Evidence Shows
AOD-9604, a growth hormone fragment, failed its obesity trials: in 536 adults, weight loss beyond placebo was under 1 kg and the developer ended the program in 2007. FDA advisers voted 12 to 0 against compounding it.
9 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Found
People who want clinician visits billed to commercial insurance, with compounded medication in the plan price
From $359/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $89/mo
Get started →